Trial Profile
Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Luminespib (Primary) ; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 12 Jul 2019 Trial has been completed in Norway, according to European Clinical Trials Database record.
- 23 Jan 2017 Status changed from completed to discontinued.
- 16 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.